Kidney Transplantation in Patients with Fabry Disease—A Case Series from a Single Romanian Center
Authors:
- Elena Emanuela RusuERElena Emanuela Rusu
- Teodor CăluşiTCTeodor Căluşi
- Bogdan Marian SorohanBSBogdan Marian Sorohan
- Dorina-Beatrice TacuDTDorina-Beatrice Tacu
- Corina ȚincuCȚCorina Țincu
- Ruxandra-Oana JurcuțRJRuxandra-Oana Jurcuț
- Robert AdamRARobert Adam
- Adriana MursăAMAdriana Mursă
- Diana-Silvia ZilişteanuDZDiana-Silvia Zilişteanu
- Bogdan StănciulescuBSBogdan Stănciulescu
- Sonia BălănicăSBSonia Bălănică
- Bogdan ObrişcăBOBogdan Obrişcă
Preprint
- 15 October 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Fabry disease (FD) is a rare, X-linked, lysosomal storage multisystemic disorder which may lead to kidney failure and require kidney transplantation (KT). Data on long-term kidney allograft outcomes and the evolution of systemic FD under dis-ease-specific therapy after KT remain limited. We retrospectively evaluated six kidney transplant recipients (KTRs) with FD followed in our center for median tine after KT of 7 years (range, 4-13). Five patients (83.3%) were males and five had a classic Fabry phe-notype. At last follow-up patient survival was 100% and five out of six KTR had a func-tional kidney graft. Among KTRs with a functioning graft, the median change is esti-mated glomerular filtration rate from 1-year to last follow-up was +3.3 ml/min/1.73m2 (range, -50.7 to +10.5), while proteinuria remained low. One patient developed late an-tibody-mediated rejection with de novo donor-specific antibodies and graft loss at 8 years post-transplantation. Five KTRs were receiving enzyme replacement therapy at the time of KT. Three patients were subsequently switched to migalastat and two later returned to enzyme replacement therapy. Lyso-Gb3 and cardiac structural parameters showed heterogenous longitudinal trajectories despite generally preserved kidney graft function. No cardiovascular events occurred during follow-up. These findings support KT as an effective renal replacement therapy in FD and highlight the need for contin-uous Fabry-specific therapy and multidisciplinary surveillance after transplantation.Keywords
All Related Versions
This publication has 39 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Prevalence of Fabry disease in patients with chronic kidney disease: A systematic review and meta-analysisMolecular Genetics and Metabolism, 2023
- European expert consensus statement on therapeutic goals in Fabry diseaseMolecular Genetics and Metabolism, 2018
- An atypical p.N215S variant of Fabry disease with end-stage renal failureMolecular Genetics and Metabolism Reports, 2018
- Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry studyMolecular Genetics & Genomic Medicine, 2018
- Fabry disease revisited: Management and treatment recommendations for adult patientsMolecular Genetics and Metabolism, 2018
- Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry RegistryMolecular Genetics and Metabolism, 2008
- Kidney Transplantation Improves Survival and Is Indicated in Fabry’s DiseaseTransplantation Proceedings, 2005
- Patients with Fabry disease on dialysis in the United StatesKidney International, 2002
- A Case of Fabry’s Disease With Normal Kidney Function at 10 Years After Successful Renal TransplantationTransplantation Proceedings, 1998